Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

properties of the s-EH inhibitors to the stage where we could present a convincing picture to venture groups of compounds ready to move to the clinic."

In 2005, the company raised more than $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.

Today, the biotech company, based in Hayward, is dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders, Hammock said. It is billed as the "world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology."

"Our main goal," Hammock said, "was to set up a system of a science-driven company where we reduce the cost of drug registration by using very good incisive science. We also want to reward and motivate the people who do the work; provide a funding and training environment to help teach students and postgraduates to write proposals; and allow scientists to move between an academic and industrial environment in the early stage to help determine career directions."

Another goal: a low-cost, affordable drug. "The sickest people in the world, of course, cannot pay for the drugs they need," Hammock said. "The chemistry developed around the s-EH inhibitors allows us to make powerful but inexpensive drugs that could be produced in developing countries."

Meanwhile, the clinical trials under way represent two firsts, said James Sabry, president and chief executive officer of Arte Therapeutics. "This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension."

."AR9281 has demonstrated an excellent
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... Mich---University of Michigan researchers have determined that most types ... evidence that the deadliest form of skin cancer does ... model. In addition, the researchers found that melanoma ... genes on and off, making the malignant cells a ...
... WASHINGTON Though the massive glaciers of the greater ... steps now to help the region,s communities prepare for ... their lives, according to a new report. Programs that ... needed to adequately address these impacts, the report states. ...
... Ill. University of Illinois researchers are using a new ... in biology the relationship between cell mass and growth ... and bioengineering professor Rashid Bashir, published its results in the ... Academy of Sciences . "It,s merging micro-scale engineering and ...
Cached Biology News:More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5Microsensors offer first look at whether cell mass affects growth rate 2
(Date:3/2/2015)... 02, 2015 Resilinc released ... report which summarizes and analyzes nearly 700 unique ... EventWatch™ 24X7 global event monitoring and alert reporting ... a free trial period of the email service to ... that can negatively impact revenue, market share, customer satisfaction, ...
(Date:3/2/2015)... 2015 VLP Therapeutics, LLC. ("VLP"), a ... on the research and development of therapeutic and ... upon a novel and proprietary vaccine technology, today ... Grant Award from the Montgomery County Department of ... is awarded to life sciences companies in ...
(Date:3/2/2015)... March 2, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics, today announced that it ... Healthcare Conference in Miami, FL at the Loews Miami Beach ... officer of Pfenex, will provide an overview of ... 12th at 9:00 am ET. A live audio webcast and ...
(Date:3/2/2015)... , March 2, 2015 ... to bottom.   Moments ago, Analysts Review ... Sunshine Heart (NASDAQ: SSH ), Synergetics ... Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... Analysts Review provides a single unified platform for investors, to ...
Breaking Biology Technology:Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4
... June 15 Finesse Solutions, LLC, San Jose, CA, a ... its move from a facility in Santa Clara, CA, to ... new address is 71 Daggett Drive, San Jose, CA, 95134. ... from Irvine, CA to Silicon Valley. , , The ...
... MedPredict Market Research, a global provider of pharmaceutical competitive ... entitled "Thought Leader Insight & Analysis: Alzheimer,s Disease," designed ... companies with a stake in the market for diagnostics ... http://www.medpredict.com/website/home.aspx ). , , MedPredict ...
... , - Improving Research ... today announced a new partnership agreement with NextBio,provider of ... discover, and share knowledge locked within public and proprietary,data ... of NextBio,s unique set of ontology-based semantic tools and ...
Cached Biology Technology:New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 3Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 4
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Biology Products: